{"commentary":{"count":19,"free_build_floor":8,"listing_floor":3,"by_channel":{"podcast":8,"x_thread":7,"youtube":4},"note":"Indexed podcasts, YouTube videos and X posts that name this trial. A report screens them, searches for more and cites what clinicians said when it is built."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT02367781\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's public preview; the full report is still bought."},"name":"IMpower130","nct_id":"NCT02367781","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=impower130-nct02367781. The price is fixed at order. We build the report after the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":1250,"size":"standard","size_rule":"Standard: 13–40 commentary sources"},"registry":{"acronym":"IMpower130","arms":[{"description":"Participants received intravenous (IV) infusion of atezolizumab and carboplatin on Day 1 of each 21-day cycle, and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until loss of clinical benefit whichever occurred first during induction treatment phase. Participants received IV infusion of atezolizumab during maintenance treatment phase until loss of clinical benefit.","label":"Arm A (Atezolizumab+Nab-Paclitaxel+Carboplatin)","type":"EXPERIMENTAL"},{"description":"Participants received IV infusion of carboplatin on Day 1 and nab-paclitaxel on Days 1, 8, and 15 of each 21-day cycle for 4 or 6 cycles or until disease progression whichever occurred first during induction treatment phase. Participants received best supportive care during maintenance treatment phase. Switch maintenance to pemetrexed was also permitted. Participants who were consented prior to approval of protocol Version 5 were given the option to cross over to receive atezolizumab as monotherapy until disease progression.","label":"Arm B (Nab-Paclitaxel+Carboplatin)","type":"ACTIVE_COMPARATOR"}],"collaborators":[],"completion_date":{"date":"2021-01-18","type":"ACTUAL"},"conditions":["Carcinoma, Non-Squamous Non-Small Cell Lung"],"enrollment":{"count":723,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody","type":"DRUG"},{"name":"Carboplatin","type":"DRUG"},{"name":"Nab-Paclitaxel","type":"DRUG"},{"name":"Pemetrexed","type":"DRUG"}],"last_update":"2021-08-09","lead_sponsor":"Hoffmann-La Roche","official_title":"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer","overall_status":"COMPLETED","phases":["PHASE3"],"primary_completion_date":{"date":"2018-03-15","type":"ACTUAL"},"primary_outcomes":[{"measure":"Progression-Free Survival (PFS) as Determined by the Investigator Using Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) in the ITT-WT Population","timeFrame":"Up to approximately 35 months after first patient enrolled"},{"measure":"Overall Survival (OS) in the ITT-WT Population","timeFrame":"Up to approximately 35 months after first patient enrolled"}],"references":[{"citation":"Socinski MA, Jotte RM, Cappuzzo F, Nishio M, Mok TSK, Reck M, Finley GG, Kaul MD, Yu W, Paranthaman N, Bara I, West HJ. Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non-Small Cell Lung Cancer: Pooled Analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 Randomized Clinical Trials. JAMA Oncol. 2023 Apr 1;9(4):527-535. doi: 10.1001/jamaoncol.2022.7711.","pmid":"36795388","type":"DERIVED"},{"citation":"Ton TGN, Pal N, Trinh H, Mahrus S, Bretscher MT, Machado RJM, Sadetsky N, Chaudhary N, Lu MW, Riely GJ. Replication of Overall Survival, Progression-Free Survival, and Overall Response in Chemotherapy Arms of Non-Small Cell Lung Cancer Trials Using Real-World Data. Clin Cancer Res. 2022 Jul 1;28(13):2844-2853. doi: 10.1158/1078-0432.CCR-22-0471.","pmid":"35511917","type":"DERIVED"},{"citation":"West H, McCleod M, Hussein M, Morabito A, Rittmeyer A, Conter HJ, Kopp HG, Daniel D, McCune S, Mekhail T, Zer A, Reinmuth N, Sadiq A, Sandler A, Lin W, Ochi Lohmann T, Archer V, Wang L, Kowanetz M, Cappuzzo F. Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019 Jul;20(7):924-937. doi: 10.1016/S1470-2045(19)30167-6. Epub 2019 May 20.","pmid":"31122901","type":"DERIVED"}],"start_date":{"date":"2015-04-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Study of Atezolizumab in Combination With Carboplatin Plus (+) Nab-Paclitaxel Compared With Carboplatin+Nab-Paclitaxel in Participants With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT02367781"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"2.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/impower130-nct02367781"}